2022 marked the 10th anniversary of our International Linked Clinical Trials (iLCT) programme. In their 2022 paper, McFarthing et al. reported that 40% of all potentially disease-modifying treatments that were in active clinical trial for Parkinson’s, had been evaluated by the iLCT committee.

The latest updates from the iLCT programme

Cure Parkinson’s announces new role: Head of Pipeline Research

Cure Parkinson’s is delighted to announce that Dr Leah Mursaleen has been appointed to the newly created role of Head of Pipeline Research to drive forward early-stage research to ensure that more potential new treatments for Parkinson’s are ready to be taken to clinical trial as soon as possible.

Read more here
The 2022 iLCT meeting

At the annual meeting, the International Linked Clinical Trials (iLCT) committee meet to rank and prioritise therapies that may have the potential to modify the course of Parkinson’s progression. In addition to this primary task, the iLCT committee receives updates of ongoing studies and clinical trial-related topics.

Read more here
The iLCT committee appoints a new chair

Cure Parkinson’s and Van Andel Institute are delighted to announce that Professor David K. Simon, of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States

Read more here
Research focus

The importance of the International Linked Clinical Trials (iLCT) programme in the search for a cure. Here, Research Officer Rosie Fuest discusses our flagship research programme.

Read more here
The 2022 Parkinson’s drug development pipeline report

The Cure Parkinson’s research team and a group of Parkinson’s advocates have produced an annual report outlining the current development pipeline of new drug-based treatments for Parkinson’s. Nearly 40% of all disease-modifying clinical trials currently happening have been previously assessed by our International Linked Clinical Trials programme (iLCT).

Read more here
The Cure Collective

Now in its fourth year, the Cure Collective solely supports the vital work of the iLCT; find out more about this celebrated fundraising initiative.

Read more here
The liraglutide trial results

Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the iLCT liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living and non-motor symptoms in people with Parkinson’s.

Read more here
The Anle138b trial results

Anle138b is a new drug that was prioritised by our International Linked Clinical Trials (iLCT) committee in 2019 as a potential drug to target the build-up of alpha synuclein, a protein that clumps together in Parkinson’s and is involved in the progression of the disease.

Read more here
The International Linked Clinical Trials (iLCT) programme

Cure Parkinson’s iLCT programme seeks to significantly reduce the time taken to bring much needed and potentially curative treatments into the clinic for the Parkinson’s community; there are iLCT trials that are actively recruiting participants now.

Find out more about taking part

CEO Will Cook and Director of Research Dr. Richard Wyse discuss the founding and development of one of the most successful and pioneering drug-repurposing and repositioning programmes in the world.